Abstract:See Josephs (doi:10.1093/brain/awx367) for a scientific commentary on this article.In many neurodegenerative disorders, familial forms have provided important insights into the pathogenesis of their corresponding sporadic forms. The first mutations associated with frontotemporal lobar degeneration (FTLD) were found in the microtubule-associated protein tau (MAPT) gene on chromosome 17 in families with frontotemporal degeneration and parkinsonism (FTDP-17). However, it was soon discovered that 50% of these families had a nearby mutation in progranulin. Regardless, the original FTDP-17 nomenclature has been retained for patients with MAPT mutations, with such patients currently classified independently from the different sporadic forms of FTLD with tau-immunoreactive inclusions (FTLD-tau). The separate classification of familial FTLD with MAPT mutations implies that familial forms cannot inform on the pathogenesis of the different sporadic forms of FTLD-tau. To test this assumption, this study pathologically assessed all FTLD-tau cases with a known MAPT mutation held by the Sydney and Cambridge Brain Banks, and compared them to four cases of four subtypes of sporadic FTLD-tau, in addition to published case reports. Ten FTLD-tau cases with a MAPT mutation (K257T, S305S, P301L, IVS10+16, R406W) were screened for the core differentiating neuropathological features used to diagnose the different sporadic FTLD-tau subtypes to determine whether the categorical separation of MAPT mutations from sporadic FTLD-tau is valid. Compared with sporadic cases, FTLD-tau cases with MAPT mutations had similar mean disease duration but were younger at age of symptom onset (55 ± 4 years versus 70 ± 6 years). Interestingly, FTLD-tau cases with MAPT mutations had similar patterns and severity of neuropathological features to sporadic FTLD-tau subtypes and could be classified into: Pick's disease (K257T), corticobasal degeneration (S305S, IVS10‰+‰16, R406W), progressive supranuclear palsy (S305S) or globular glial tauopathy (P301L, IVS10‰+‰16). The finding that the S305S mutation could be classified into two tauopathies suggests additional modifying factors. Assessment of our cases and previous reports suggests that distinct MAPT mutations result in particular FTLD-tau subtypes, supporting the concept that they are likely to inform on the varied cellular mechanisms involved in distinctive forms of sporadic FTLD-tau. As such, FTLD-tau cases with MAPT mutations should be considered familial forms of FTLD-tau subtypes rather than a separate FTDP-17 category, and continued research on the effects of different mutations more focused on modelling their impact to produce the very different sporadic FTLD-tau pathologies in animal and cellular models.

Genetic forms of tauopathies: inherited causes and implications of Alzheimer’s disease-like TAU pathology in primary and secondary tauopathies

Tau physiology and pathomechanisms in frontotemporal lobar degeneration

Tau in neurodegenerative disease

The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy

Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals

Tau in the Pathophysiology of Parkinson’s Disease

The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome

Tauopathies: new perspectives and challenges

Atypical, non-standard functions of the microtubule associated Tau protein

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Emerging Diagnostic and Therapeutic Strategies for Tauopathies

Tau Protein and Tauopathies: Exploring Tau Protein‐Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies.

Cellular Biology of Tau Diversity and Pathogenic Conformers

The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death

Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease

The Sulfation Code of Tauopathies: Heparan Sulfate Proteoglycans in the Prion Like Spread of Tau Pathology

The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Primary age-related tauopathy (PART): a common pathology associated with human aging

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology

Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies